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Incidence of melanoma, the deadliest form of skin cancer,
continues to increase among older adults and young women
worldwide despite signiﬁcant eﬀorts to raise awareness and
informthepublicaboutriskfactorssuchassunexposure,use
of tanning salon, and the need to monitor skin for potential
neoplastic lesions. Whether this increase is due to an actual
rise in the number of individuals that develop the disease or
due to an increase in classiﬁcation of lesions as melanoma
remains contentious; however it is indisputable that lim-
ited progress has been made in improving treatment of
malignant melanoma or mortality rates. While new targeted
agents against BRAF and immunotherapies directed against
CTLA4 are showing great promise in clinical trials, FDA-
approved therapies for melanoma remain largely ineﬀective,
highlighting the need to better understand the mechanisms
underlying disease initiation and progression. Melanoma
results from malignant transformation of melanocytes. The
most frequent site of transformation is in the skin where
melanocytes produce the pigment melanin that confers skin
color and protects against sun-induced damage. Multiple
factors contribute to melanoma risk, including genetic
predisposition and environmental risk factors such as sun
exposure. In this special issue, we present six papers that
review some of the crucial issues currently being investigated
in the melanoma ﬁeld.
B. Bandarchi et al. provide a broad review of malig-
nant melanoma, from epidemiology and risk factors to
classiﬁcation and clinical features, highlighting some of the
genes that play a role in disease progression. Furthermore
they review treatment options and discuss the 2009 Amer-
ican Joint Committee on Cancer Melanoma Staging and
Classiﬁcation.
J. A. H. Lee explores the relationship between incidence
rates for in situ and invasive melanoma, proposing that the
trends may in fact provide clues to the mechanisms that
underlie development and progression of melanoma.
R. Ria et al. review the events and consequences of
increasing vascularization during tumorigenesis and sum-
marize the most relevant cytokines involved. They also
detail the roles of melanoma-produced factors involved in
interacting with or modifying the extracellular environment
infavourofneovascularizingprocesses.Finally,theseauthors
discuss recent eﬀorts to therapeutically target tumor vas-
cularization in patients using a variety of small molecule
inhibitors, concluding that there remains much room for
improvement.
AgroupledbyAnneliesdeKlein(T.vandenBoschetal.)
comparecutaneousanduvealmelanomasandﬁndthatwhile
diagnosis and therapy options are similar, there are telling
diﬀerences in the biology of these malignances. For example,
cutaneous melanomas may metastasize to a variety of organs
in the body while most uveal melanomas metastasize to
the liver; the authors point out that this diﬀerence is
likely due to the absence of lymphatic vessels associated
with the eye. Perhaps most interesting are the cytogenetic
diﬀerences discussed, the most prominent example being
that monosomy 3 is a common feature of uveal melanomas
which is rarer in the cutaneous disease.2 Dermatology Research and Practice
J. F. G. Cohen-Solal and coworkers review melanoma’s
capacity for immune escape, reminding us of extensive
studies conducted by themselves and other groups which
show that expression of Fc-gamma receptor decoys serves to
prevent immune eﬀector cells from recognizing melanoma
cells and providing answers as to how melanoma has so
far avoided targeted immunotherapy. They close with the
hopeful note that it may be possible to design Fc fragments
with reduced aﬃnity for decoys and higher aﬃnity for
immune-functional receptors.
The Italian group of M. Sanzo et al. review chronic stress
as a possible cofactor in the progression of melanoma. As
treatment of this dreaded disease continues to be ineﬀective,
this hypothesis is worth exploring. They suggest in their
paper that despite understanding biological mechanisms
underlying local and distant metastases, the eﬀect of stress
mediator molecules such as catecholamines may increase
progression. These ﬁndings point to the complexity of can-
cers in that chronic stress including both psychological and
environmental factors may inﬂuence biological pathways.
Finally, these authors suggest that intervention targeting
these catecholinergic hormones in addition to psychological
and social support may represent a valid approach in the
treatment of advanced melanoma.
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